Analysts take a look at UDG Healthcare plc (LON:UDG) having this to say.

January 12, 2018 - By Louis Casey

 Analysts take a look at UDG Healthcare plc (LON:UDG) having this to say.

UDG Healthcare plc (LON:UDG) Ratings Coverage

Among 10 analysts covering UDG Healthcare PLC (LON:UDG), 4 have Buy rating, 1 Sell and 5 Hold. Therefore 40% are positive. UDG Healthcare PLC had 97 analyst reports since July 31, 2015 according to SRatingsIntel. The stock has “Hold” rating by N+1 Singer on Thursday, August 3. As per Thursday, August 3, the company rating was maintained by Liberum Capital. On Tuesday, July 26 the stock rating was maintained by Jefferies with “Buy”. The stock of UDG Healthcare plc (LON:UDG) earned “Add” rating by Peel Hunt on Thursday, August 10. The stock of UDG Healthcare plc (LON:UDG) has “Buy” rating given on Monday, September 18 by Cantor Fitzgerald. The rating was maintained by Goodbody with “Buy” on Friday, April 1. The firm earned “Buy” rating on Thursday, February 2 by Liberum Capital. Berenberg upgraded UDG Healthcare plc (LON:UDG) rating on Friday, February 12. Berenberg has “Buy” rating and GBX 585 target. Liberum Capital downgraded UDG Healthcare plc (LON:UDG) on Monday, August 14 to “Hold” rating. The firm has “Buy” rating given on Tuesday, November 24 by Jefferies. Below is a list of UDG Healthcare plc (LON:UDG) latest ratings and price target changes.

19/12/2017 Broker: Peel Hunt Rating: Add Old Target: GBX 880.00 New Target: GBX 880.00 Maintain
07/12/2017 Broker: Peel Hunt Rating: Add Old Target: GBX 860.00 New Target: GBX 880.00 Maintain
04/12/2017 Broker: Jefferies Rating: Hold Old Target: GBX 855.00 New Target: GBX 800.00 Maintain
30/11/2017 Broker: Stifel Nicolaus Rating: Hold Old Target: GBX 815.00 New Target: GBX 815.00 Maintain
28/11/2017 Broker: N+1 Singer Rating: Hold Maintain
28/11/2017 Broker: Liberum Capital Rating: Hold Old Target: GBX 884.00 New Target: GBX 884.00 Maintain
28/11/2017 Broker: Peel Hunt Rating: Add Old Target: GBX 860.00 New Target: GBX 860.00 Maintain
15/11/2017 Broker: Liberum Capital Rating: Hold Old Target: GBX 884.00 New Target: GBX 884.00 Maintain
09/11/2017 Broker: Numis Securities Rating: Reduce Old Target: GBX 765.00 New Target: GBX 765.00 Downgrade
01/11/2017 Broker: N+1 Singer Rating: Hold Old Target: GBX 770.00 New Target: GBX 841.00 Maintain

The stock increased 1.99% or GBX 15.5 during the last trading session, reaching GBX 793.5. About 744,271 shares traded or 5.71% up from the average. UDG Healthcare plc (LON:UDG) has 0.00% since January 12, 2017 and is . It has underperformed by 16.70% the S&P500.

UDG Healthcare plc, together with its subsidiaries, provides clinical, commercial, communication, and packaging services to the healthcare industry in the Republic of Ireland, the United Kingdom, North America, and continental Europe. The company has market cap of 1.97 billion GBP. It operates through three divisions: Ashfield, Sharp, and Aquilant. It has a 27.55 P/E ratio. The Ashfield segment offers commercialization and clinical services for the pharmaceutical and healthcare industry that comprise supporting healthcare professionals and patients at various stages of the product life cycle, as well as provides field and contact center sales teams, healthcare communications, patient support, audit, advisory, medical information, and event management services to approximately 300 healthcare companies.

More important recent UDG Healthcare plc (LON:UDG) news were published by: Reuters.com which released: “UDG Healthcare to sell two units to McKesson for $466 million” on September 18, 2015, also Nasdaq.com published article titled: “UDG Healthcare Appoints Nigel Clerkin As CFO”, Gurufocus.com published: “UDG Healthcare PLC” on November 11, 2016. More interesting news about UDG Healthcare plc (LON:UDG) was released by: Prnewswire.com and their article: “Clayton, Dubilier & Rice Names Liam FitzGerald, Former CEO of UDG Healthcare …” with publication date: January 09, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: